Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720
- Author
- BALER, M. R1 2 ; GEORGE, S. L3 4 ; LARSON, R. A10 ; SANFORD, B. L4 ; MROZEK, K5 ; KOLITZ, J. E6 ; MOORE, J. O7 ; STONE, R. M8 ; POWELL, B. L9 ; CALIGIURI, M. A5 ; BLOOMFIELD, C. D5
[1] University of Maryland Department of Medicine and Greenebaum Cancer Center, Baltimore, MD, United States
[2] Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, United States
[3] Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, United States
[4] CALGB Statistical Center, Duke University Medical Center, Durham, NC, United States
[5] The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States
[6] Division of Hematology/Oncology, Monter Cancer Center, Hofstra North Shore-LIJ School of Medicine, Manhasset, NY, United States
[7] Department of Medicine, Duke University Medical Center, Durham, NC, United States
[8] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
[9] Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC, United States
[10] Department of Medicine, University of Chicago, Chicago, IL, United States
Cancer and Leukemia Group B - Source
Leukemia. 2011, Vol 25, Num 5, pp 800-807, 8 p ; ref : 40 ref
- CODEN
- LEUKED
- ISSN
- 0887-6924
- Scientific domain
- Medical oncology; Hematology
- Publisher
- Nature Publishing Group, Avenel, NJ
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- acute myeloid leukemia age daunorubicin dose escalation etoposide
- Keyword (fr)
- Age Anticancéreux Cancer Daunorubicine Dose croissante Etoposide Homme Hématologie Leucémie aiguë myéloblastique Lymphocyte B Personne âgée Protocole thérapeutique Tumeur maligne Hémopathie lymphoïde B Anthracyclines Antimitotique DNA topoisomerase (ATP-hydrolysing) Dérivé de la podophyllotoxine Enzyme Hémopathie maligne Inhibiteur de la topoisomérase II Inhibiteur enzyme Isomerases
- Keyword (en)
- Age Antineoplastic agent Cancer Daunorubicin Increasing dose Etoposide Human Hematology Acute myelogenous leukemia B-Lymphocyte Elderly Therapeutic protocol Malignant tumor B cell neoplasm Anthracyclins Antimitotic DNA topoisomerase (ATP-hydrolysing) Podophyllotoxin derivatives Enzyme Malignant hemopathy Topoisomerase II inhibitor Enzyme inhibitor Isomerases
- Keyword (es)
- Edad Anticanceroso Cáncer Daunorubicina Dosis creciente Etopósido Hombre Hematología Leucemia aguda mieloblástica Linfocito B Anciano Protocolo terapéutico Tumor maligno Antraciclinas Antimitótico DNA topoisomerase (ATP-hydrolysing) Podofilotoxina derivado Enzima Hemopatía maligna Inhibidor topoisomerase II Inhibidor enzima Isomerases
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B19 Hematologic and hematopoietic diseases / 002B19B Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
- Discipline
- Blood diseases
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 24166141
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:170:\"Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Leukemia\";s:9:\"\u0000*\u0000stitle\";s:8:\"Leukemia\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"800\";s:8:\"\u0000*\u0000epage\";s:3:\"807\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0887-6924\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"BALER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:12:\"GEORGE, S. L\";i:1;s:12:\"LARSON, R. A\";i:2;s:13:\"SANFORD, B. L\";i:3;s:9:\"MROZEK, K\";i:4;s:12:\"KOLITZ, J. E\";i:5;s:11:\"MOORE, J. O\";i:6;s:11:\"STONE, R. M\";i:7;s:12:\"POWELL, B. L\";i:8;s:15:\"CALIGIURI, M. A\";i:9;s:16:\"BLOOMFIELD, C. D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEUKED\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:170:\"Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720\";s:8:\"\u0000*\u0000place\";s:10:\"Avenel, NJ\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:170:\"Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Leukemia\";s:9:\"\u0000*\u0000stitle\";s:8:\"Leukemia\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"800\";s:8:\"\u0000*\u0000epage\";s:3:\"807\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0887-6924\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"BALER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:12:\"GEORGE, S. L\";i:1;s:12:\"LARSON, R. A\";i:2;s:13:\"SANFORD, B. L\";i:3;s:9:\"MROZEK, K\";i:4;s:12:\"KOLITZ, J. E\";i:5;s:11:\"MOORE, J. O\";i:6;s:11:\"STONE, R. M\";i:7;s:12:\"POWELL, B. L\";i:8;s:15:\"CALIGIURI, M. A\";i:9;s:16:\"BLOOMFIELD, C. D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEUKED\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:170:\"Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720\";s:8:\"\u0000*\u0000place\";s:10:\"Avenel, NJ\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:170:\"Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Leukemia\";s:9:\"\u0000*\u0000stitle\";s:8:\"Leukemia\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"800\";s:8:\"\u0000*\u0000epage\";s:3:\"807\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0887-6924\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"BALER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:12:\"GEORGE, S. L\";i:1;s:12:\"LARSON, R. A\";i:2;s:13:\"SANFORD, B. L\";i:3;s:9:\"MROZEK, K\";i:4;s:12:\"KOLITZ, J. E\";i:5;s:11:\"MOORE, J. O\";i:6;s:11:\"STONE, R. M\";i:7;s:12:\"POWELL, B. L\";i:8;s:15:\"CALIGIURI, M. A\";i:9;s:16:\"BLOOMFIELD, C. D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEUKED\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:170:\"Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720\";s:8:\"\u0000*\u0000place\";s:10:\"Avenel, NJ\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:170:\"Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Leukemia\";s:9:\"\u0000*\u0000stitle\";s:8:\"Leukemia\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"800\";s:8:\"\u0000*\u0000epage\";s:3:\"807\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0887-6924\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"BALER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:12:\"GEORGE, S. L\";i:1;s:12:\"LARSON, R. A\";i:2;s:13:\"SANFORD, B. L\";i:3;s:9:\"MROZEK, K\";i:4;s:12:\"KOLITZ, J. E\";i:5;s:11:\"MOORE, J. O\";i:6;s:11:\"STONE, R. M\";i:7;s:12:\"POWELL, B. L\";i:8;s:15:\"CALIGIURI, M. A\";i:9;s:16:\"BLOOMFIELD, C. D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEUKED\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:170:\"Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720\";s:8:\"\u0000*\u0000place\";s:10:\"Avenel, NJ\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:170:\"Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Leukemia\";s:9:\"\u0000*\u0000stitle\";s:8:\"Leukemia\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"800\";s:8:\"\u0000*\u0000epage\";s:3:\"807\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0887-6924\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"BALER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:12:\"GEORGE, S. L\";i:1;s:12:\"LARSON, R. A\";i:2;s:13:\"SANFORD, B. L\";i:3;s:9:\"MROZEK, K\";i:4;s:12:\"KOLITZ, J. E\";i:5;s:11:\"MOORE, J. O\";i:6;s:11:\"STONE, R. M\";i:7;s:12:\"POWELL, B. L\";i:8;s:15:\"CALIGIURI, M. A\";i:9;s:16:\"BLOOMFIELD, C. D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEUKED\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:170:\"Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720\";s:8:\"\u0000*\u0000place\";s:10:\"Avenel, NJ\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
